Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Evaluating Orlistat For Potential Serious Risks

This article was originally published in The Tan Sheet

Executive Summary

FDA is evaluating whether recent adverse event reports of rectal bleeding signal a potential serious risk identified with orlistat - the active ingredient in Roche's Rx diet drug Xenical and GlaxoSmithKline's OTC weight-loss product alli
Advertisement

Related Content

Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
FDA evaluates orlistat
FDA evaluates orlistat
FDA evaluates orlistat
Acetaminophen Risk Management On Tap For Joint Advisory Panel
Acetaminophen Risk Management On Tap For Joint Advisory Panel
Alli first centralized switch

Topics

Advertisement
UsernamePublicRestriction

Register

PS102584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel